Is Strong Q3 Beat And Higher Guidance Altering The Investment Case For Collegium Pharmaceutical (COLL)? [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
This stronger outlook underscores how demand for Collegium's abuse-deterrent, extended-release pain treatments is translating into faster-than-anticipated business momentum and scale. Next, we'll examine how Collegium's upbeat revenue guidance and forecast-beating Q3 performance influence its existing investment narrative and risk profile. Uncover the next big thing with financially sound penny stocks that balance risk and reward To own Collegium, you need to believe that its focused pain and ADHD portfolio, especially abuse deterrent therapies, can offset concentration, regulatory and patent expiry risks. The Q3 revenue beat and higher guidance strengthen the near term catalyst of portfolio scale and cash generation, but do not materially change the biggest risk around looming patent cliffs and potential generic competition later this decade. The most directly relevant recent announcement is the repeated raising of full year 2024 and 2025 revenue guidance, most recently to U
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- 3 Unpopular Stocks We Find Risky [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Collegium Pharmaceutical (NASDAQ:COLL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
- Collegium Pharmaceutical (COLL): Revisiting Valuation After Fresh Coverage and Ongoing Earnings Outperformance [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
COLL
Earnings
- 11/6/25 - Beat
COLL
Sec Filings
- 12/17/25 - Form 144
- 12/10/25 - Form 4
- 12/9/25 - Form 4
- COLL's page on the SEC website